Evidence map›Paper›PMID 39812686›Full record

ArticleJournal of neurology2025

Differential diagnosis in immune checkpoint inhibitors neurotoxicity.

Catherine R Garcia, Ian J Robertson, Timothy A Gregory, Anza Zahid, Behrang Amini, Carlos Kamiya-Matsuoka, Sudhakar Tummala

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine R GarciaDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cgarcia18@mdanderson.org.ORCID http://orcid.org/0000-0002-6361-0127
Ian J RobertsonDepartment of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Timothy A GregoryDepartment of Neurology, Madigan Army Medical Center, Tacoma, WA, USA.
Anza ZahidDepartment of Neurology, Houston Methodist Hospital, Houston, TX, USA.
Behrang AminiDepartment of Musculoskeletal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carlos Kamiya-MatsuokaDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sudhakar TummalaDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurologic symptoms seen in patients receiving immune checkpoint inhibitors (ICI) may not be entirely caused by immunotoxicity. We aim to highlight these confounding conditions through clinical cases to encourage early recognition and management.

methodsWe describe a series of seven cases from our institution that were treated with ICI and presented with Neurologic symptoms and were diagnosed with superimposed conditions beyond immunotoxicity.

resultsA total of 7 cases are described that include acute motor axonal neuropathy with vitamin B12 deficiency, lumbosacral radiculopathy with Wernicke's, Herpes simplex virus (HSV) encephalitis reactivation, central nervous system vasculitis with renal vasculitis, myositis with fasciitis, myositis with fixed clinical deficit at resolution, and synovitis with accompanying carpal tunnel syndrome. Primary cancer site included lung adenocarcinoma (2/7), melanoma (4/7), and oropharyngeal squamous cell carcinoma (1/7). All patients had received treatment with more than one ICI. Median number of cycles prior to neurotoxicity was 3 cycles. DISCUSSION: Neurologic symptoms seen in patients receiving ICI may include other causes beyond immunotoxicity.

Indexed as

Immune Checkpoint InhibitorsNeurotoxicity SyndromesAgedAged, 80 and overDiagnosis, DifferentialFemaleHumansMaleMiddle AgedImmune Checkpoint InhibitorsAdverse eventImmune checkpoint inhibitorImmunotherapyNeurotoxicity

Identifiers

PMID39812686

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.